Prolia (denosumab) - Important Safety Information from AMGEN Ireland Limited as approved by the Health Products Regulatory Authority

Notice type: 3rd Party Publications

Date: 16/09/2014

 

Background Information Or Related Documents:
Important Safety Information communication from AMGEN Ireland Limited on updated information to minimize the risk of osteonecrosis of the jaw and hypocalcaemia during treatment with Prolia (denosumab).

Important Safety Information - Prolia (denosumab)


« Back